Replimune Slashes Workforce After FDA Rejects Drug Replimune will cut ~40% of staff after an FDA complete response letter; shares plunged in trading on Apr 11, 2026 (Seeking Alpha), raising financing and execution risks.

Replimune Slashes Workforce After FDA Rejects Drug: Replimune will cut ~40% of staff after an FDA complete response letter; shares plunged in trading on Apr 11, 2026 (Seeking Alpha), raising financing and execution risks. 👈 Read full analysis #Replimune #FDAApproval #Layoffs #PharmaNews #Biotech

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

Assertio Downgraded After Garda Acquisition H.C. Wainwright cut Assertio’s rating on Apr 9, 2026 after the Garda deal; the downgrade signals integration and financing risk for ASRT (Investing.com, Apr 9, 2026).

Assertio Downgraded After Garda Acquisition: H.C. Wainwright cut Assertio’s rating on Apr 9, 2026 after the Garda deal; the downgrade signals integration and financing risk for ASRT (Investing.com, Apr 9, 2026). 👈 Read full analysis #Assertio #GardaAcquisition #PharmaNews #StockMarket #Finance

Plus Therapeutics Jumps After FDA Grants Orphan-Drug Status Plus Therapeutics received FDA orphan-drug status on Apr 8, 2026; orphan designation gives 7 years of U.S. exclusivity, changing commercial optionality for PSTV.

Plus Therapeutics Jumps After FDA Grants Orphan-Drug Status: Plus Therapeutics received FDA orphan-drug status on Apr 8, 2026; orphan designation gives 7 years of U.S. exclusivity, changing commercial… 👈 Read full analysis #PlusTherapeutics #OrphanDrug #FDAApproval #HealthcareInvestment #PharmaNews

Fennec Pharmaceuticals Rating Reiterated After Study Expansion H.C. Wainwright reiterated coverage on Apr 8, 2026 after Fennec expanded trial enrollment from 30 to 85 patients (+183%), per company release.

Fennec Pharmaceuticals Rating Reiterated After Study Expansion: H.C. Wainwright reiterated coverage on Apr 8, 2026 after Fennec expanded trial enrollment from 30 to 85 patients (+183%), per… 👈 Read full analysis #FennecPharmaceuticals #ClinicalTrials #PharmaNews #Healthcare #ResearchExpansion

Inhibikase Trials Advance; H.C. Wainwright Reiterates Rating H.C. Wainwright reiterated coverage on Apr 8, 2026 after Inhibikase reported trial progress on Apr 6, 2026; the note maintained prior views with limited immediate market impact.

Inhibikase Trials Advance; H.C. Wainwright Reiterates Rating: H.C. Wainwright reiterated coverage on Apr 8, 2026 after Inhibikase reported trial progress on Apr 6, 2026; the note maintained prior views… 👈 Read full analysis #Inhibikase #ClinicalTrials #PharmaNews #InvestmentInsights #MarketReactions

Unicycive Therapeutics Director Gaurav Aggarwal Resigns Unicycive director Gaurav Aggarwal resigned on Apr 6, 2026 per an SEC 8‑K (Investing.com); governance follow‑up in the next 2–6 weeks will determine impact.

Unicycive Therapeutics Director Gaurav Aggarwal Resigns: Unicycive director Gaurav Aggarwal resigned on Apr 6, 2026 per an SEC 8‑K (Investing.com); governance follow‑up in the next 2–6 weeks will determine impact. 👈 Read full analysis #Unicycive #Biotech #Investing #SmallCapStocks #PharmaNews

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

Nektar Reiterated by Oppenheimer After Alopecia Data Oppenheimer reaffirmed Nektar's rating on Apr 1, 2026; alopecia affects ~2% of people (NEJM), making clinical readouts the key re-rating catalysts.

Nektar Reiterated by Oppenheimer After Alopecia Data: Oppenheimer reaffirmed Nektar's rating on Apr 1, 2026; alopecia affects ~2% of people (NEJM), making clinical readouts the key re-rating catalysts. 👈 Read full analysis #Nektar #Oppenheimer #Alopecia #ClinicalTrials #PharmaNews

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

Lilly Acquires Centessa for Up to $7.8B Eli Lilly agreed to buy Centessa for up to $7.8bn (announced Mar 31, 2026), targeting experimental narcolepsy drugs for a condition affecting ~0.05% of the population.

Lilly Acquires Centessa for Up to $7.8B: Eli Lilly agreed to buy Centessa for up to $7.8bn (announced Mar 31, 2026), targeting experimental narcolepsy drugs for a condition affecting ~0.05% of the population. 👈 Read full analysis #EliLilly #Centessa #PharmaNews #Biotech #Narcolepsy

Denali Therapeutics Gets $200m from Royalty Deal Denali received $200m upfront under a royalty agreement (SEC filing, Mar 31, 2026), a material liquidity event that changes future revenue rights and valuation dynamics.

Denali Therapeutics Gets $200m from Royalty Deal: Denali received $200m upfront under a royalty agreement (SEC filing, Mar 31, 2026), a material liquidity event that changes future revenue rights and… 👈 Read full analysis #DenaliTherapeutics #RoyaltyDeal #Biotechnology #Investment #PharmaNews

🚨 Novedad en China 🇨🇳

Nuevos fármacos e indicaciones aprobados: de asma y sinusitis crónica a psoriasis e hidradenitis supurativa.

🌍 Más acceso a terapias innovadoras para enfermedades inflamatorias.

#ChinaPharma #PharmaNews #Biológicos #NuevosMedicamentos #DengYueMed

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

Journey Medical Misses EPS by $0.50 Journey Medical missed EPS by $0.50 and reported revenue below estimates on Mar 26, 2026 (Investing.com); investors should review the company’s 8-K and guidance for line-item detail.

Journey Medical Misses EPS by $0.50: Journey Medical missed EPS by $0.50 and reported revenue below estimates on Mar 26, 2026 (Investing.com); investors should review the company’s 8-K and guidance for line-item… 👈 Read full analysis #JourneyMedical #EPSMiss #Investing #PharmaNews #RevenueReported

Corcept Gains FDA Approval for Cancer Therapy Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for the company.

Corcept Gains FDA Approval for Cancer Therapy: Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for… 👈 Read full analysis #Corcept #FDAApproval #CancerTherapy #PharmaNews #HealthcareInnovation

Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer

#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh

Merck Nears Deal to Buy Terns Pharmaceuticals Bloomberg reported on Mar 25, 2026 that Merck is in advanced talks to acquire Terns Pharmaceuticals; watch filings and deal structure for valuation impacts.

Merck Nears Deal to Buy Terns Pharmaceuticals: Bloomberg reported on Mar 25, 2026 that Merck is in advanced talks to acquire Terns Pharmaceuticals; watch filings and deal structure for valuation impacts. 👈 Read full analysis #Merck #TernsPharmaceuticals #Biotech #MergersAndAcquisitions #PharmaNews

Crinetics Pharma COO to Step Down, Shares Weaken Crinetics announced a COO departure on Mar 23, 2026; Nasdaq-listed CRNX saw elevated intraday volume and volatility, per Seeking Alpha and exchange data.

Crinetics Pharma COO to Step Down, Shares Weaken: Crinetics announced a COO departure on Mar 23, 2026; Nasdaq-listed CRNX saw elevated intraday volume and volatility, per Seeking Alpha and exchange data. 👈 Read full analysis #CrineticsPharma #COO #Nasdaq #CRNX #PharmaNews

Gilead Nears $2bn Ouro Medicines Deal Gilead is reported to be nearing a $2.0bn acquisition of Ouro Medicines (FT, Mar 23, 2026); the deal would be a targeted bolt-on versus Gilead's $21bn Immunomedics purchase in 2020.

Gilead Nears $2bn Ouro Medicines Deal: Gilead is reported to be nearing a $2.0bn acquisition of Ouro Medicines (FT, Mar 23, 2026); the deal would be a targeted bolt-on versus Gilead's $21bn Immunomedics purchase in… 👈 Read full analysis #Gilead #OuroMedicines #Acquisition #PharmaNews #Healthcare

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

ESA de acción prolongada de Sansheng Pharma (Rosai EPO alfa / Xinbi’ao) aprobada para anemia por ERC en hemodiálisis 💊

¿Menos dosis y mejor control de Hb?

🎥 Mira el video

#CKD #AnemiaRenal #Hemodiálisis #ESA #PharmaNews #Biopharma

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

FDA Flags Aurobindo Pharma Unit In Rajasthan - IndiaWest News FDA Flags Aurobindo Pharma Unit In Rajasthan.

FDA Flags Aurobindo Pharma Unit In Rajasthan

Full Story: indiawest.com/fda-flags-au...

#FDA #AurobindoPharma #PharmaNews #NewDelhi #BusinessNews #HealthcareIndustry #DrugSafety #RegulatoryUpdate #Pharmaceuticals #IndiaBusiness

ONCOassist Universal Link Opening ONCOassist app...

🔗 Read more: bit.ly/ONCOnews-19M...

#ONCOnews #OncoAlert #OncEd #OvarianCancer #CancerResearch #Oncology #PrecisionMedicine #PersonalizedMedicine #CompanionDiagnostics #Biomarkers #TargetedTherapy #CancerCare #OncologyNews #ClinicalTrials #DrugDevelopment #FDAApproval #PharmaNews #MedTech

In today’s headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

Iran War Impact: Are Medicines Getting Costlier in India? Rising tensions involving Iran, Israel, and the United States are beginning to disrupt supply chains, increasing raw material costs and raising concerns about higher prices and possible shortages of c...

Iran-US can be reason for medicine price hike in India

#MedicinePrices #PharmaNews #IndiaNews #IranUSConflict #HealthcareCosts #SupplyChain #BreakingNews #GlobalEconomy #Pharmaceuticals #InflationImpact

www.indiaweekly.biz/iran-us-conf...

In yesterday's headlines: pharmaphorum.com/news

#news #pharma #lifesciences #pharmanews #pharmaindustry

Analysten: Könnte stärker wirken als Eli Lillys Medikament

Der Markt für Abnehmmedikamente wurde bisher von Eli Lilly und Novo Nordisk dominiert – jetzt kommt ein neuer Player! 🚀

Wenn Sobis Medikament zugelassen wird, könnte sich das Marktgefüge komplett ändern. ⚖️

#EliLilly #PharmaNews